INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE;UNIVERSITE PARIS-SUD;INSTITUT GUSTAVE ROUSSY;ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
发明人:
Franck Carbonnel
申请号：
US16494095
公开号：
US20200129566A1
申请日:
2018.03.22
申请国别(地区):
US
年份:
2020
代理人:
摘要：
Embodiments of the present disclosure relate to methods for ex vivo determining whether a patient with metastatic melanoma is likely to benefit from a treatment with an anti CTLA-4 molecule, preferably ipilimumab, by analyzing the gut microbiota in a fecal sample from said patient.
